CD274 and head and neck cancer: Fortunately, anti‐PD‐1 and anti‐PD‐L1 agents have revolutionized head and neck cancer therapy.15, 16, 17 To date, three PD‐1 inhibitors (pembrolizumab, nivolumab and cemiplimab) and three PD‐L1 inhibitors (atezolizumab, durvalumab and avelumab) have been approved by the US Food and Drug Administration (FDA).